First Doses of AXAL Administered to Phase 3 Cervical Cancer Trial Participants
News
The first doses of Advaxis‘ axalimogene filolisbac, or AXAL, have been administered to women with advanced cervical cancer in a Phase 3 trial of the treatment’s effectiveness after chemotherapy and radiation. The multicenter, ... Read more